Discover why JNJ's long-term buy rating is supported by its blue-chip status, profitability, and diverse revenue lines, ...
Johnson & Johnson closed $25.19 below its 52-week high ($168.85), which the company reached on September 4th.
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...
Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback